Pharmacokinetic values and anti-SL-401 antibody titer
| Subject number . | Cmax values on day1/day5 (ng/mL) . | Half-life values on day 1/day5 (minutes) . | Anti-SL-401 antibody pretreatment/days15-39 (μg/mL) . |
|---|---|---|---|
| 1 | 0/7 | –/50 | 6/34 |
| 2 | 0/– | −/− | 8/4 590 |
| 3 | 22/2 | 40/10 | 0.5/35 |
| 4 | 8/18 | 30/30 | 1/– |
| 5 | 0/ND | −/− | 4/10 000 |
| 5B | 0/0 | −/− | 4 400/5 300 |
| 6 | 23/20 | 49/47 | 0.5/1 847 |
| 7 | 70/50 | 54/82 | 0.6/2 700 |
| 8 | 47/– | 89/– | 34/– |
| 9 | 55/– | 74/– | 11/– |
| 10 | 14/35 | 35/84 | 0.26/– |
| 11 | 40/– | 44/– | 2/– |
| Mean (SD) | 25 (24)/22 (18) | 52 (20)/51 (29) | 6 (10)/3 201 (3 749) |
| Subject number . | Cmax values on day1/day5 (ng/mL) . | Half-life values on day 1/day5 (minutes) . | Anti-SL-401 antibody pretreatment/days15-39 (μg/mL) . |
|---|---|---|---|
| 1 | 0/7 | –/50 | 6/34 |
| 2 | 0/– | −/− | 8/4 590 |
| 3 | 22/2 | 40/10 | 0.5/35 |
| 4 | 8/18 | 30/30 | 1/– |
| 5 | 0/ND | −/− | 4/10 000 |
| 5B | 0/0 | −/− | 4 400/5 300 |
| 6 | 23/20 | 49/47 | 0.5/1 847 |
| 7 | 70/50 | 54/82 | 0.6/2 700 |
| 8 | 47/– | 89/– | 34/– |
| 9 | 55/– | 74/– | 11/– |
| 10 | 14/35 | 35/84 | 0.26/– |
| 11 | 40/– | 44/– | 2/– |
| Mean (SD) | 25 (24)/22 (18) | 52 (20)/51 (29) | 6 (10)/3 201 (3 749) |
Patient 5B excluded from mean and standard deviation calculation.
SD, standard deviation; –, either patient sample not obtained or patient did not receive fifth daily dose so day 5 PK not evaluable; ND, not determined.